Andrae Vandross

891 total citations
19 papers, 547 citations indexed

About

Andrae Vandross is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Andrae Vandross has authored 19 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Hematology. Recurrent topics in Andrae Vandross's work include Multiple Myeloma Research and Treatments (3 papers), Health and Medical Research Impacts (3 papers) and Diversity and Career in Medicine (3 papers). Andrae Vandross is often cited by papers focused on Multiple Myeloma Research and Treatments (3 papers), Health and Medical Research Impacts (3 papers) and Diversity and Career in Medicine (3 papers). Andrae Vandross collaborates with scholars based in United States, Israel and Canada. Andrae Vandross's co-authors include Vinay Prasad, Chul Kim, Mauricio Burotto, Jason Rho, Senthil Selvaraj, Nancy T. Ho, Steven Quinn, Michael Cheung, Adam S. Cifu and Satish J Chacko and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Andrae Vandross

18 papers receiving 529 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrae Vandross United States 7 227 108 103 91 85 19 547
Anthony J. Hatswell United Kingdom 17 338 1.5× 80 0.7× 204 2.0× 108 1.2× 57 0.7× 65 826
Joshua Ray Switzerland 15 294 1.3× 93 0.9× 90 0.9× 46 0.5× 86 1.0× 45 875
Steven K. Cheng United States 9 259 1.1× 72 0.7× 57 0.6× 96 1.1× 331 3.9× 13 586
Ellie Siden Canada 10 85 0.4× 54 0.5× 81 0.8× 110 1.2× 79 0.9× 15 527
Sophie Beale United Kingdom 17 209 0.9× 88 0.8× 125 1.2× 35 0.4× 57 0.7× 42 911
Jonca Bull United States 7 107 0.5× 61 0.6× 59 0.6× 42 0.5× 188 2.2× 10 493
Riha Vaidya United States 11 352 1.6× 162 1.5× 220 2.1× 56 0.6× 425 5.0× 41 889
Ágnes Benedict United States 18 418 1.8× 88 0.8× 283 2.7× 87 1.0× 56 0.7× 57 1.2k
Sarah Goring United States 15 93 0.4× 42 0.4× 154 1.5× 67 0.7× 38 0.4× 37 613
Saskia Knies Netherlands 14 348 1.5× 174 1.6× 46 0.4× 40 0.4× 34 0.4× 40 632

Countries citing papers authored by Andrae Vandross

Since Specialization
Citations

This map shows the geographic impact of Andrae Vandross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrae Vandross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrae Vandross more than expected).

Fields of papers citing papers by Andrae Vandross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrae Vandross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrae Vandross. The network helps show where Andrae Vandross may publish in the future.

Co-authorship network of co-authors of Andrae Vandross

This figure shows the co-authorship network connecting the top 25 collaborators of Andrae Vandross. A scholar is included among the top collaborators of Andrae Vandross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrae Vandross. Andrae Vandross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Piha‐Paul, Sarina A., Anthony W. Tolcher, Andrae Vandross, Alexander I. Spira, & Mark R. Burns. (2025). Phase I dose-escalation trial of AMXT 1501 dicaprate plus difluoromethylornithine: a dual-agent approach targeting immunosuppressive polyamine metabolism. ESMO Open. 10(9). 105576–105576.
2.
Dumbrava, Ecaterina E., Idoia Rodríguez, Mohamad A. Salkeni, et al.. (2025). Abstract CT154: BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study. Cancer Research. 85(8_Supplement_2). CT154–CT154. 1 indexed citations
3.
Schram, Alison M., John A. Thompson, Andrae Vandross, et al.. (2024). Phase I analysis from the PYNNACLE phase I/II study of PC14586 in the subgroup of patients with advanced ovarian cancer harboring a TP53 Y220C mutation. Gynecologic Oncology. 190. S67–S67. 1 indexed citations
4.
Babu, Sunil, Shunsuke Kondo, Alexander I. Spira, et al.. (2023). 1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors. Annals of Oncology. 34. S647–S648. 2 indexed citations
5.
Tolcher, Anthony W., Andrae Vandross, Melissa M. Johnson, et al.. (2022). A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 in subjects with inoperable locally advanced or metastatic solid tumors (301). Gynecologic Oncology. 166. S158–S158. 2 indexed citations
6.
7.
Johnson, Melissa M., Susanna V. Ulahannan, Andrae Vandross, et al.. (2022). Abstract CT254: A first-in-human phase 1 study of the safety and pharmacokinetics of XB002 in patients with inoperable locally advanced or metastatic solid tumors. Cancer Research. 82(12_Supplement). CT254–CT254. 1 indexed citations
8.
Powderly, John D., et al.. (2021). 519 A first-in-human, multicenter, phase 1/2, open-label study of XTX101 in patients with advanced solid tumors. SHILAP Revista de lepidopterología. A549–A549. 1 indexed citations
9.
Hanna, Ramy M., Andrae Vandross, Jonathan E. Zuckerman, et al.. (2019). Light and heavy chain deposition revealed by repeat renal biopsy after inconclusive initial biopsy. 5. 1 indexed citations
10.
Hanna, Ramy M., et al.. (2019). Atypical hemolytic uremic syndrome and complement blockade. Current Opinion in Nephrology & Hypertension. 28(3). 278–287. 12 indexed citations
11.
Vandross, Andrae. (2017). Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma. Seminars in Oncology. 44(6). 381–384. 5 indexed citations
12.
Larson, Sarah M., Monica Mead, Andrae Vandross, et al.. (2017). Abstract 136: Phospho-S6 levels correlate with response to Copanlisib (BAY 80-6946) in multiple myeloma. Cancer Research. 77(13_Supplement). 136–136. 1 indexed citations
13.
Vandross, Andrae, Vinay Prasad, & Sham Mailankody. (2016). ASCO Plenary Sessions: impact, legacy, future. Seminars in Oncology. 43(3). 321–326. 3 indexed citations
14.
Prasad, Vinay & Andrae Vandross. (2015). Characteristics of Exceptional or Super Responders to Cancer Drugs. Mayo Clinic Proceedings. 90(12). 1639–1649. 29 indexed citations
15.
Prasad, Vinay, Chul Kim, Mauricio Burotto, & Andrae Vandross. (2015). The Strength of Association Between Surrogate End Points and Survival in Oncology. JAMA Internal Medicine. 175(8). 1389–1389. 256 indexed citations
16.
Prasad, Vinay, et al.. (2014). Can a Resident's Publication Record Predict Fellowship Publications?. PLoS ONE. 9(3). e90140–e90140. 10 indexed citations
17.
Prasad, Vinay, Andrae Vandross, Michael Cheung, et al.. (2013). A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices. Mayo Clinic Proceedings. 88(8). 790–798. 194 indexed citations
18.
Prasad, Vinay, et al.. (2012). Publication Trends Among Internal Medicine Residents and Graduates. The American Journal of Medicine. 125(9). 939–944. 13 indexed citations
19.
Vandross, Andrae. (2012). Cardiovascular Primary Prevention. Archives of Internal Medicine. 172(8). 656–656. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthony J. Hatswell Breakdown of academic impact, for papers by Joshua Ray Breakdown of academic impact, for papers by Steven K. Cheng Breakdown of academic impact, for papers by Ellie Siden Breakdown of academic impact, for papers by Sophie Beale Breakdown of academic impact, for papers by Jonca Bull Breakdown of academic impact, for papers by Riha Vaidya Breakdown of academic impact, for papers by Ágnes Benedict Breakdown of academic impact, for papers by Sarah Goring Breakdown of academic impact, for papers by Saskia Knies
Rankless by CCL
2026